Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
IN RE REVLIMID & THALOMID PURCHASER ANTITRUST LITIGATION
Case Number:
2:19-cv-07532
Court:
Nature of Suit:
Judge:
Firms
- Baldassare & Mara
- Boies Schiller
- Glancy Prongay
- Hangley Aronchick
- Hill Wallack
- Jones Day
- Kenny Nachwalter
- Lowey Dannenberg
- Miller Shah LLP
- Pashman Stein
- Spector Roseman
- Walsh Pizzi
Companies
- Blue Cross Blue Shield Association
- Bristol-Myers Squibb Co.
- Celgene Corp.
- CVS Health Corp.
- Dr. Reddy's Laboratories Ltd.
- Florida Blue
- Fraternal Order of Police
- Health Care Service Corp.
- Humana Inc.
- Intermountain Health
- Intermountain Healthcare Inc.
- Mayo Foundation for Medical Education and Research
- Teva Pharmaceutical Industries Ltd.
- The Cigna Group
Sectors & Industries:
-
May 22, 2024
Teva, Bristol-Myers Cite Bystolic Against Cancer Drug Case
Celgene and parent Bristol-Myers Squibb pointed a New Jersey federal judge to the dismissal, recently upheld by the Second Circuit, of an antitrust suit over delayed generic competition to AbbVie's hypertension treatment Bystolic to argue the same logic applies to their bid to duck antitrust claims over cancer therapies.
-
December 05, 2023
Bristol-Myers Decries Blue Cross Unit's Last-Minute Dropout
Celgene and parent Bristol-Myers Squibb expressed frustration Tuesday about the timing of a Blue Cross unit's decision to bow out as a plaintiff in New Jersey federal court antitrust litigation accusing the drugmakers of delaying generic competition to blockbuster cancer treatments, raising concerns the insurer might shirk its discovery obligations.
-
April 21, 2023
Celgene, BMS, Teva Can't Pause Cancer Drugs Antitrust Suit
A New Jersey federal magistrate judge refused Friday to pump the brakes on consolidated antitrust lawsuits accusing Celgene and parent Bristol-Myers Squibb of conspiring with generic drugmakers Teva and Natco to delay generic competition to blockbuster cancer treatments, preferring to get a move on with the years-old litigation.